{"id":"oncaspar","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Hypoalbuminemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Elevated transaminase","drugRate":"","severity":"common","organSystem":""},{"effect":"Febrile neutropenia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertriglyceridemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperglycemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Bilirubin increased","drugRate":"","severity":"common","organSystem":""},{"effect":"Pancreatitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Abnormal clotting studies","drugRate":"","severity":"common","organSystem":""},{"effect":"Embolic and thrombotic events","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypersensitivity","drugRate":"","severity":"common","organSystem":""},{"effect":"Sepsis","drugRate":"","severity":"common","organSystem":""},{"effect":"Infections","drugRate":"","severity":"common","organSystem":""},{"effect":"Clinical allergic reactions","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperbilirubinemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Coagulopathies","drugRate":"","severity":"common","organSystem":""},{"effect":"Bronchospasm","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypotension","drugRate":"","severity":"common","organSystem":""},{"effect":"Laryngeal edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Systemic rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Urticaria","drugRate":"","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Thrombosis","drugRate":"4%","severity":"serious"},{"effect":"Hyperglycemia requiring insulin therapy","drugRate":"3%","severity":"serious"},{"effect":"Pancreatitis","drugRate":"1%","severity":"serious"},{"effect":"Embolic and thrombotic events","drugRate":"","severity":"serious"},{"effect":"Sepsis","drugRate":"","severity":"serious"},{"effect":"Infections","drugRate":"","severity":"serious"},{"effect":"Hypersensitivity","drugRate":"","severity":"serious"},{"effect":"Abnormal clotting studies","drugRate":"","severity":"serious"},{"effect":"Febrile neutropenia","drugRate":"","severity":"serious"},{"effect":"Elevated transaminase","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["PEGASPARGASE","NSC #624239)"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Oncaspar","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:42:26.107206+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:42:31.211272+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oncaspar","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:42:31.576429+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Asparagine hydrolytic enzyme","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:42:32.624781+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108546/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:42:32.290158+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"ac7b6a6f-6ddb-48c6-8088-d8a8e3fea6ce","title":"ONCASPAR (PEGASPARGASE) INJECTION, SOLUTION [SERVIER PHARMACEUTICALS LLC]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T03:41:08.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:42:34.065698+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Acute lymphoid leukemia","diseaseId":"acute-lymphoid-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT06314334","phase":"PHASE2","title":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-04","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":210},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT05602194","phase":"PHASE3","title":"Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-08-14","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","enrollment":440},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07457177","phase":"PHASE2","title":"Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL","status":"NOT_YET_RECRUITING","sponsor":"LIANG WANG","startDate":"2026-02-10","conditions":"NK T-Cell Lymphoma","enrollment":40},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05157971","phase":"PHASE1","title":"Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-03-17","conditions":"B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT04127227","phase":"PHASE2","title":"Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-10-09","conditions":"NK/T Cell Lymphoma Nos","enrollment":34},{"nctId":"NCT03150693","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2017-09-20","conditions":"B Acute Lymphoblastic Leukemia","enrollment":310},{"nctId":"NCT05289687","phase":"PHASE2","title":"Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL","status":"RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2023-05-25","conditions":"T-cell Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02981628","phase":"PHASE2","title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-06-19","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT00400946","phase":"PHASE3","title":"05-001: Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-04","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":800},{"nctId":"NCT01574274","phase":"PHASE2","title":"SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-06","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":240},{"nctId":"NCT05700448","phase":"PHASE3","title":"Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2026-06","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":150},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT06069830","phase":"NA","title":"PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-12-06","conditions":"NK-T-Cell Lymphoma, Extranodal","enrollment":89},{"nctId":"NCT00590915","phase":"","title":"Erwinase Master Treatment Protocol","status":"NO_LONGER_AVAILABLE","sponsor":"Phoenix Children's Hospital","startDate":"","conditions":"Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia","enrollment":""},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT05848687","phase":"PHASE1, PHASE2","title":"TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II","status":"RECRUITING","sponsor":"Tanja Andrea Gruber","startDate":"2023-11-03","conditions":"Lymphoblastic Leukemia","enrollment":90},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT03808610","phase":"PHASE1, PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":160},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)","enrollment":67},{"nctId":"NCT02879643","phase":"PHASE1","title":"Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2017-01-31","conditions":"ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute","enrollment":29},{"nctId":"NCT04501614","phase":"PHASE1, PHASE2","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-02-24","conditions":"Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)","enrollment":11},{"nctId":"NCT05192889","phase":"PHASE1, PHASE2","title":"Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-08-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT01920737","phase":"PHASE2","title":"A Novel \"Pediatric-Inspired\" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08-07","conditions":"Leukemia","enrollment":39},{"nctId":"NCT02716233","phase":"PHASE3","title":"A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-09-19","conditions":"Acute Lymphoblastic Leukemia","enrollment":2044},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia","enrollment":461},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT03564678","phase":"PHASE2","title":"Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-17","conditions":"Acute Lymphoblastic Leukemia, Hyperbilirubinemia","enrollment":10},{"nctId":"NCT03719105","phase":"EARLY_PHASE1","title":"Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2019-03-01","conditions":"NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma","enrollment":40},{"nctId":"NCT05660473","phase":"PHASE2","title":"Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-08-01","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":100},{"nctId":"NCT06559553","phase":"PHASE1, PHASE2","title":"\"Selinexor+Pegaspargase+Dexamethasone\"in Ⅰ/Ⅱ NKTCL","status":"RECRUITING","sponsor":"Mingzhi Zhang","startDate":"2024-09-01","conditions":"NKTCL, Selinexor","enrollment":50},{"nctId":"NCT05521087","phase":"PHASE1","title":"A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-26","conditions":"Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT03817320","phase":"PHASE1, PHASE2","title":"PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2019-02-12","conditions":"ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood","enrollment":24},{"nctId":"NCT05386576","phase":"EARLY_PHASE1","title":"A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-06-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":12},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT07000617","phase":"PHASE2","title":"A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-03-21","conditions":"NK/T Cell Lymphoma","enrollment":57},{"nctId":"NCT03384654","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-14","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":47},{"nctId":"NCT06034561","phase":"PHASE2","title":"Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2024-04-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission","enrollment":50},{"nctId":"NCT05959720","phase":"","title":"Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-09-05","conditions":"Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality","enrollment":180},{"nctId":"NCT06953739","phase":"PHASE3","title":"A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-05-01","conditions":"NK-T-Cell Lymphoma, Extranodal","enrollment":60},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT01190930","phase":"PHASE3","title":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2010-08-09","conditions":"Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma","enrollment":9350},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT03844360","phase":"PHASE4","title":"Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","status":"RECRUITING","sponsor":"Wei Zhao","startDate":"2016-01-31","conditions":"Hematological Neoplasms","enrollment":1500},{"nctId":"NCT03792256","phase":"PHASE1","title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2019-04-11","conditions":"Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma","enrollment":12},{"nctId":"NCT04043494","phase":"PHASE3","title":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"University Hospital Muenster","startDate":"2019-08-23","conditions":"Lymphoblastic Lymphoma, Childhood","enrollment":683},{"nctId":"NCT04365036","phase":"PHASE3","title":"A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-05-03","conditions":"NK/T Cell Lymphoma Nos","enrollment":207},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":78},{"nctId":"NCT06824883","phase":"PHASE2","title":"Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05-20","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":49},{"nctId":"NCT01228331","phase":"PHASE2, PHASE3","title":"Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2010-10","conditions":"Leukemia","enrollment":745},{"nctId":"NCT06176027","phase":"PHASE1, PHASE2","title":"Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas","status":"RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-10-01","conditions":"Relapsed Peripheral T-Cell Lymphomas, Refractory Peripheral T-Cell Lymphomas","enrollment":52},{"nctId":"NCT06583083","phase":"PHASE2","title":"Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-22","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":84},{"nctId":"NCT06573151","phase":"PHASE2","title":"Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT06554626","phase":"PHASE2","title":"Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-08-15","conditions":"Precursor B-Cell Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT05873322","phase":"","title":"Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-08-30","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Induced Diabetes Mellitus, Impaired Glucose Tolerance","enrollment":100},{"nctId":"NCT05326516","phase":"PHASE1","title":"A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2022-03-09","conditions":"Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT06527781","phase":"PHASE1","title":"A Study of PD5K3 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2023-11-27","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Lymphoma","enrollment":28},{"nctId":"NCT01523977","phase":"PHASE1","title":"Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-11","conditions":"Acute Lymphoblastic Leukemia","enrollment":22},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT02393859","phase":"PHASE3","title":"Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-11-10","conditions":"Leukemia, Acute Lymphoblastic","enrollment":111},{"nctId":"NCT06210750","phase":"PHASE2","title":"Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-09","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT06406556","phase":"PHASE2","title":"Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2016-03-01","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":90},{"nctId":"NCT06376721","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-04-14","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma","enrollment":43},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275},{"nctId":"NCT03267030","phase":"PHASE2","title":"Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase","status":"COMPLETED","sponsor":"Birgitte Klug Albertsen","startDate":"2017-08-23","conditions":"Acute Lymphoblastic Leukemia","enrollment":55},{"nctId":"NCT04509466","phase":"PHASE1, PHASE2","title":"Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL","status":"TERMINATED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-09-15","conditions":"Extranodal NK/T-cell Lymphoma, Nasal Type","enrollment":41},{"nctId":"NCT02013167","phase":"PHASE3","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-01-03","conditions":"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","enrollment":405},{"nctId":"NCT05058755","phase":"NA","title":"Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2021-09-17","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":62},{"nctId":"NCT04845035","phase":"PHASE2","title":"Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT06255795","phase":"PHASE3","title":"The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-02-15","conditions":"Extranodal Natural Killer T Cell Lymphoma","enrollment":142},{"nctId":"NCT04843150","phase":"","title":"Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2020-07-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":320},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT06195735","phase":"","title":"Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2020-07-17","conditions":"Acute Lymphoblastic Leukemia","enrollment":649},{"nctId":"NCT04956666","phase":"PHASE2","title":"A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2021-06-15","conditions":"Acute Lymphoblastic Leukemia","enrollment":75},{"nctId":"NCT03962465","phase":"PHASE1","title":"Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2022-07-22","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT04954326","phase":"PHASE2","title":"A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2021-05-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":89},{"nctId":"NCT02396043","phase":"PHASE2","title":"Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":"Lymphoma, Lymphoblastic","enrollment":50},{"nctId":"NCT02705508","phase":"PHASE2","title":"PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-02","conditions":"Treatment Refusal","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL2108546"},"formularyStatus":[],"_approvalHistory":[{"date":"20200617","type":"SUPPL","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"},{"date":"20190103","type":"SUPPL","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"},{"date":"20161007","type":"SUPPL","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"},{"date":"20060724","type":"SUPPL","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"},{"date":"19940201","type":"ORIG","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"},{"date":"20140422","type":"SUPPL","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"},{"date":"20110323","type":"SUPPL","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"},{"date":"20240313","type":"SUPPL","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"},{"date":"20221222","type":"SUPPL","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"},{"date":"20211102","type":"SUPPL","sponsor":"SIGMA TAU","applicationNumber":"BLA103411"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":33,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Oncaspar","genericName":"Oncaspar","companyName":"Dana-Farber Cancer Institute","companyId":"dana-farber-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":19,"withResults":5},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:42:34.065698+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}